Erasca announces departure of CMO Wei Lin, promotion of Shannon Morris as new CMO

Erasca, Inc.

CMO Wei Lin resigned to pursue other opportunities; last day April 21, 2023, no disagreement cited.
Shannon Morris, former SVP Clinical Development, promoted to CMO effective April 10, 2023.
Dr. Morris brings 20+ years oncology experience; led Cosela NDA at G1 Therapeutics and Imfinzi BLA at MedImmune.
New employment terms: base salary $470,000, 40% target bonus, and option to purchase 375,000 shares vesting monthly.
Dr. Morris reclassified from Tier 2 to Tier 1 Covered Employee under Severance Plan.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Wei Lin

Chief Medical Officer

ERAS · Erasca, Inc.

Effective: 2023-04-21
Successor: Shannon R. Morris
Filed: April 10, 2023, 7:59 PM ET

On April 4, 2023, Wei Lin, M.D. notified Erasca, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company to pursue other opportunities.

Appointed

Shannon R. Morris

Chief Medical Officer

ERAS · Erasca, Inc.

Effective: 2023-04-10
Filed: April 10, 2023, 7:59 PM ET

Effective as of April 10, 2023, Shannon R. Morris, M.D., Ph.D. has been promoted to the position of the Chief Medical Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Wei Lin resigned as Chief Medical Officer at Erasca, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On April 4, 2023, Wei Lin, M.D. notified Erasca, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company to pursue other opportunities.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Shannon R. Morris was appointed as Chief Medical Officer at Erasca, Inc..

Action: promoted
Role: Chief Medical Officer

Exact text from the filing

Effective as of April 10, 2023, Shannon R. Morris, M.D., Ph.D. has been promoted to the position of the Chief Medical Officer of the Company.

View on SEC.gov

Erasca, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-012240

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.